购物车
- 全部删除
- 您的购物车当前为空
Mavorixafor trihydrochloride is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs (IC50s: 1 and 9 nM).
Mavorixafor trihydrochloride is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs (IC50s: 1 and 9 nM).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 720 | 5日内发货 | |
5 mg | ¥ 1,260 | 5日内发货 | |
25 mg | ¥ 5,380 | 5日内发货 | |
50 mg | ¥ 6,990 | 5日内发货 | |
100 mg | ¥ 11,600 | 5日内发货 |
产品描述 | Mavorixafor trihydrochloride is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs (IC50s: 1 and 9 nM). |
靶点活性 | HIV-1 (NL4.3 strain):9 nM (in PBMCs), HIV-1:26 nM (IC90, in PBMCs), HIV-1 (NL4.3 strain):1 nM (in MT-4 cells), HIV-1 (NL4.3 strain):3 nM (IC90, in MT-4 cells), [125I]-SDF-CXCR4:13 nM |
体外活性 | Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2) [1]. Mavorixafor (6.6 μM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells [2]. |
体内活性 | Mavorixafor (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice and lowers the expression of human Alu DNA in mice without body weight loss [2]. |
别名 | AMD-070 trihydrochloride |
分子量 | 458.86 |
分子式 | C21H30Cl3N5 |
CAS No. | 2309699-17-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
溶解度信息 | DMSO: 6 mg/mL (13.08 mM), Sonication is recommended. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.